Morgan Stanley Call 52.5 BMY 20.1.../ DE000ME66BE3 /
08/07/2024 20:59:07 | Chg.- | Bid09:38:01 | Ask09:38:01 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.061EUR | - | 0.059 Bid Size: 20,000 |
0.070 Ask Size: 17,500 |
Bristol Myers Squibb... | 52.50 USD | 20/12/2024 | Call |
GlobeNewswire
19/06
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Re...
GlobeNewswire
18/06
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
17/06
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increa...
GlobeNewswire
17/06
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angel...
GlobeNewswire
14/06
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored...
GlobeNewswire
11/06
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
11/06
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
GlobeNewswire
10/06
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
31/05
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire
30/05
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
23/05
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...